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Cystic fibrosis (CF) is the most common lethal genetic
disease in Caucasians. The cystic fibrosis gene codes for an
integral membrane protein, the cystic fibrosis transmem-
brane conductance regulator (CFTR). It is a cAMP-depend-
ant chloride channel with the capacity of not only excreting
organic anions as glutathione and cytochrome P450
metabolites conjugated to glutathione but has also other
regulatory functions [1]. Some of the most important
symptoms of CF are not directly the consequence of
impaired chloride transport. The pulmonary inflammation
and infection resulting in pulmonary failure is the major
cause of death. Different medications have been used tos 4 (2005) 27–34ed by Elsevier B.V. All rights reserved.
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steroidal anti-phlogistics, antioxidants. . . resulting in an
important gain of life expectancy.
Recent studies give however new insights in the
possible pathophysiology of the increased sensitivity for
inflammation of CF patients. Especially the role of the
metabolism of fatty acids (FAs) is highlighted by recent
findings in CFTR / mice. Freedman et al. described a
mouse model of CF in which important abnormalities of
the FA metabolism were shown [2]. The biochemical
aberrations were corrected by oral supplementation of
pharmacological doses of docosahexaenoic acid (DHA,
22:6N3). This results in new therapeutic perspectives. The
first clinical DHA supplementation trials have already
started. This review goes into the possible rationale behind
these trials. A brief overview of the metabolism of the
essential fatty acids (EFAs) is given.2. Essential fatty acids and their metabolism
FAs as triglycerides and phospholipids are the main
components of energy production and storage. After
digestion, absorption and biosynthetic transformations, acyl
chains are not only used for triglyceride synthesis but also
become part of biomembranes after esterification to com-
plex lipids. FAs account for more than 50% of the molecular
mass of phospholipids. The fatty acid tails of the phospho-
lipids are responsible for the apolar nature of membrane
bilayers. The phospholipid membrane components influence
many membrane functions as ion channelling and transport,
endo- and exocytosis and the functions of membrane-
associated receptors and enzymes [3].
Polyunsaturated fatty acids (PUFAs), originating from
EFAs by elongation and desaturation, are precursors ofω3 
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Fig. 1. Fatty acid notation: number of carbon atoms: numbbiologically active molecules, the eicosanoids and docosa-
noids. PUFAs contribute to the control processes of nuclear
transcription, via special receptors and response elements
[4,5]. PUFAs released by agonist stimulated phospholipase
A2 (PLA2), are involved in signal transduction [6]. More-
over they are involved in activation or modulation of protein
kinase C, in direct stimulation of membrane receptors and in
interaction with guanylate cyclases. They also participate in
translocation processes of biosynthetic key-enzymes. A
diversity of acyl chains may be required to fulfil so many
different tasks [4–6].3. Interconversion of long-chain PUFAs
De novo synthesis of FAs produces mainly palmitate
(C16:0), with minor amounts of stearate (C18:0). Many
cells have the capacity for 2-carbon chain elongation of FAs
that takes place mostly in the endoplasmatic reticulum. It is
the main source of acyl chains greater than 16 carbon atoms
in membrane phospholipids.
All eukaryotic organisms contain polyenoic fatty acyl
chains in their membrane lipids. Most tissues can modify
acyl chain composition by introducing double bonds by
means of desaturases (D5, D6, D9). Linoleic acid (LA,
18:2N6) and a-linolenic acid (18:3N3) are EFAs. These
acyl chains are converted into other FAs containing 3 to 6
double bonds (Fig. 1). Arachidonic acid (AA, 20:4N6), an
N6 FA found in most tissues, can be formed from LA by
alternating sequence of D6 desaturation, chain elongation
of the 18:3N6 intermediate thus formed and D5 desa-
turation of 20:3N6 (Fig. 1). AA is a component of
phospholipids contributing to structural integrity of mem-
branes and is the primary precursor of several classes of
oxygenated derivatives.ω6 ω9 
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er of double bonds followed by biochemical series.
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abundant N3 acyl chains are eicosapentaenoic acid (EPA,
20:5N3) and DHA. The alternating sequence of desaturation
and elongation is also the primary pathway of DHA
synthesis. The N3 and N6 long chain fatty acids compete
for the same elongases and desaturases.4. Phospholipase A2
PLA2 represent a family of enzymes catalysing the
hydrolysis of glycerophospholipids at the sn-2 position,
thereby liberating free FAs. They are classified according
to their localisation and calcium dependency [7,8]. These
types of PLA2 contain different isoenzymes making the
understanding of the FA metabolism even more compli-
cated [8].
The intracellular calcium-independent phospholipases
A2 (iPLA2) is a membrane-associated enzyme that is
implicated in membrane phospholipid remodelling and
signal transduction [9]. The type IIA extracellular
secretory PLA2 (sPLA2) has been isolated from inflam-
matory fluids and cells [8,10]. This isoenzyme is
induced by pro-inflammatory stimuli and is therefore
thought to play a role in inflammatory responses [11,12].
Finally it has been demonstrated that the calcium-
dependant cytosolic PLA2 (cPLA2) and the sPLA2 areMembrane Phospholipids
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Fig. 2. Arachidonic acid is released by the action of phospholipase A2 on memb
bradykinin, angiotensin II. Some derivatives of alpha-linolenic acid, the essen
phospholipase A2, and result in antagonistic actions. The three main directions of
epoxygenation. The cyclooxygenase products of arachidonate generate prostagland
of arachidonate generate the pro-inflammatory leukotrienes, but also some biol
inflammatory lipoxins. The epoxgenation pathways result, by action of cytochrom
midchain HETEs, N-terminal HETEs and epoxyeicosatrienoic acids (EETs).linked to the cyclooxygenase (COX)-2 enzymes respon-
sible for the production of prostaglandins and thrombox-
anes [13].
PLA2 is activated by multiple agonists and cell specific
signals [14,15], resulting in the release of PUFA, precursors
of inflammatory mediators, eicosanoids [12]. The best-
studied eicosanoid system is that of AA.
Some derivatives of a-linolenic acid, the parent EFA of
the N3 series, inhibit the release of AA by phospholipase A2
and results in antagonistic effects.5. The eicosanoid production from polyunsaturated fatty
acids
5.1. Main directions of metabolism of AA
The three main directions of metabolism of AA are cy-
clooxygenation, lipoxygenation and epoxygenation (Fig. 2).
Cyclooxygenases (COXs) generate intermediates that
can be converted into prostaglandins, prostacyclins and
thromboxanes. Blocking these enzymes by ibuprofen
reduced in CF the production of COXs metabolites and
resulted in a reduced decline of pulmonary function,
weight and chest radiographic scores [16]. This type of
treatment, however has a very narrow therapeutic
window.Leukotrienes
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rane phospholipids. Phospholipase A2 is activated by multiple cell signals,
tial fatty acid of the N-3 series, inhibit the release of arachidonate by
the metabolism of arachidonate are cyclooxygenation, lipoxygenation and
ins, prostacyclin and thromboxanes of the 2 series. Lipoxygenase products
ogically very active hydroperoxyeicosatetranoates (HETEs) and the anti-
es P450, in formation of 3 categories of biologically very active products:
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hormones. They are found in virtually all tissues and organs.
Their activities are mediated by G-protein mediated PG
receptors. The same PGs have different effects on different
tissues. Consumption of N6 FAs stimulates the production of
pro-inflammatory PGs (PG2 series) derived from AA, while
consumption of N3 FA stimulates the production of anti-
inflammatory PGs (PG3 series). PGs have a wide variety of
actions but most of them cause muscular constriction and
mediate inflammation. Other effects are calcium movement,
hormone regulation and cell growth control [17,18].
Thromboxanes (TXs) whose principal pro-inflammatory
mediator is the highly unstable TXA2, a potent aggregator
of platelets and vasoconstrictor. TXs are the physiologic
antagonists of prostacyclin. An imbalance in favour of TX
will lead to initiation of platelet aggregation and an acute
inflammatory response [19].
In CF patients increased PGE2 and TXB2 , a stable
transformation product of TXA2, as well as their metabo-
lites was demonstrated at all ages [20]. They also have a
hyperaggregability due to the increased TXA2 release [21].
Prostacyclin (PGI2) is mainly produced in the endothe-
lial cells and is antagonistic to TX. It inhibits platelet
aggregation as well as the activation of leukocytes. PGI2
plays an important role in vascular function because it
inhibits platelet adhesion to the vascular endothelium and is
a powerful vasodilator [22].
Lipoxigenase (LOX) products of AA generate via the 5-
LOX the pro-inflammatory leukotrienes, via the 12-LOX
some very active hydroperoxyeicosatetraenoates and finally
via the 15-LOX the anti-inflammatory lipoxins.
Leukotrienes (LTs) are potent mediators of inflamma-
tion stimulating chemotaxis, chemokinesis, aggregation,
enhancement of lysosomal enzyme release, superoxide
anion production and ion fluxes in the leukocyte. They
promote together with the PGs endothelial permeability.
Thereby they promote the oedema formation during
inflammation [23,24].
Increased LTs are discovered in sputa of CF patients and
treatment with LT antagonists yields promising results
[25,26].
Lipoxins are endogenously generated small chemical
mediators, playing a key role in inflammation control and
resolution. These trihydroxytetraene-containing eicosanoids
are generated by tight cell to cell interactions by trans-
cellular biosynthesis [27]. Although the cellular regulation
of 15-LOX activity is not fully elucidated, an important
defect was discovered in CF lungs. The administration of
lipoxin analogues in a CF mouse model resulted in
decreased lung inflammation and infection [28].
Epoxygenation pathways result by action of different
cytochromes P450, in formation of hydroxyepoxytetrae-
noate and epoxyeicosatrienoic acids. These products mod-
ulate renal, pulmonary and cardiac function, regulate
vascular tone and are involved in the metabolism of many
other tissues [29–32].5.2. Eicosanoids from other long chain PUFAs
Besides AA several other FAs as EPA, DHA and
dihomogamma linolenic acid (20:3N6) are also substrates
for COXs, LOXs and epoxygenases. Many of these
metabolites have still unknown structure and function.
Dihomogammalinolenic acid is the precursor of anti-
inflammatory eicosanoids. It exerts however also a modu-
latory effect on cytokine production since it reduces
interleukin-10 and tumour necrosis factor alpha but leaves
interleukin-6 unaffected [33].
Christophe et al. reported increased vital capacity in CF
patients supplemented with an oil rich in gamma-linolenic
acid [34].
Eicosapentaenoic acid is a substrate for COXs, LOXs
and the epoxygenase activities resulting in products with
potent anti-inflammatory activity [35]. Many of the end
products have still unknown structure and function.
5.3. Docosahexaenoic acid derivatives
A novel series of DHA derivatives are the docosatrienes
and resolvins, present in blood, leukocytes, brain and glial
cells. They are biosynthesised via the epoxide-containing
intermediates and decrease leukocyte infiltration and glial
cell cytokine production [36]. Resolvins are produced in the
resolution phase of acute inflammation and stop neutrophil
entry and reduce exsudate [37]. They are induced by aspirin
via the acetylation of COX-2. These derivatives might
contribute to the frequently reported beneficial responses
obtained by N3 supplementation [38].6. Fatty acids in cystic fibrosis
6.1. Essential fatty acid status in cystic fibrosis
Freedman and Alvares demonstrated a membrane lipid
imbalance in mice with a targeted deletion of the CFTR
gene (CFTR /) characterized by an increased phospho-
lipid-bound AA and a decreased phospholipid-bound DHA.
This imbalance was present in the CFTR expressing organs
as lung, pancreas and ileum. By supplementing these CFTR
/ mice with high doses of DHA the membrane lipid
imbalance was reversed. The ileal hypertrophy, pathological
changes in the pancreas and the pulmonary inflammation
disappeared [2]. This observation renewed the interest in old
data.
It was known for long that CF patients often have fatty
acid deficiencies [39,40]. They display an increase of the
monounsaturated fatty acids and a decrease of the N3 and
N6 PUFA concentrations [41–44]. Although attention was
not drawn to the imbalance of N3 and N6 PUFA at the time,
it is present in the results of Lloyd-Still [45]. Clinical
symptoms of EFA deficiency, however, are rare except for
the skin manifestations in patients with severe deficiencies
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and rectal biopsies of CF patients as they described in the
CF mouse model [47].
Strandvik et al. demonstrated a correlation between the
genotype and the observed decrease in linoleic acid and
DHA [48]. Patients with the more severe mutations had
more important lipid imbalances. This is in concordance
with the observation that the FA imbalance as described by
Freedman [2] is not observed in CF mice models where
modified CFTR proteins reached the membrane [49].
It has been demonstrated that supplementation with
specific oils can influence the fatty acid profiles in CF
patients [34,50,51]. DHA fed as algal triacylglycerol is
readily absorbed, incorporated in blood and tissues and well
tolerated as proven by recent studies [52]. The clinical
relevance however remained obscure until the observations
of Freedman [2,47].
6.1.1. Aetiology of EFA deficiency in CF
The initial hypothesis was that the deficiency was secon-
dary to malnutrition, diet and pancreatic insufficiency [39].
Studies demonstrated however a lack of correlation between
the nutritional state, pancreatic function and the fatty acid
deficiency [41,48,53]. A correlation between genotype and
EFA deficiency has been described by Strandvik et al. [48].
As discussed above PUFAs are also used for production of
eicosanoids. In contrast to normal patients with EFA
deficiency, CF patients develop EFA deficiency in parallel
with increased eicosanoid production [20]. This abnormal
turnover of EFAs was reported by several groups [54–57].
Carlstedt-Duke et al. hypothesised an increased turnover of
AA [56]. They showed defective AA regulation in CF since
the release of AA by PLA2 was not blocked by dexametha-
son. They and other investigators concluded to an increased
AA release induced by defective regulation of PLA2 [56–59].
These data along with the observations in CFTR /
mice led to the speculation that the abnormalities of AA and
DHA may be primary in CF [46,56].
However, it has to be considered that these PUFAs are
very susceptible for peroxidation and the susceptibility
increases with the number of double bonds [60]. Wood et al.
demonstrated repeatedly that oxidative stress is increased in
CF and there is a strong correlation with plasma fatty acid
levels and the consumption of and high fat diets [61,62].
The clinical relevance is not yet clear since high fat diets
have proved clinical benefit despite the associated increased
peroxidation [63]. Wood et al. were able to improve
antioxidant status by supplementation with a high dose of
vitamin E, vitamin C, vitamin A, h carotene and selenium
but there was no corresponding decrease in oxidative stress
or improvement of plasma fatty acid composition [62].
6.2. Phospholipase A2 and CFTR
Pathological regulation of AA release has been suggested
by many different research groups [56–59]. It was demon-strated that in different CF cell lines the basal cPLA2
activity was increased but the amount of immunoreactive
cPLA2 was identical to the control cell lines. In response to
bradykinin only the DF508 homozygous CF cells displayed
an increase of cPLA2 activity and immunoreactive cPLA2
[64]. By cooling down the cells, which restores the delivery
of the CFTR protein to the membrane, the overstimulation
by bradykinin of PLA2 disappeared in the DF508 homo-
zygous CF cells. This difference between cells with or
without CFTR protein was also observed earlier by Levistre
et al. [58].
This could at least in part explain the heterogeneity
observed between the different genotypes.
6.3. Relation between EFA deficiency and CF symptoms
In animals EFA deficiency is known to cause liver
steatosis, increased caloric needs, increased bacterial colo-
nisation and decreased immune response [65]. Symptoms
that are very similar to some of the symptoms observed in CF.
Recently, a study on EFA status in pre-adolescent
children demonstrated a positive correlation between serum
LA levels and FEV1 as well as growth status. 20 3N9, a
marker for essential fatty acid deficiency, Ls inversely
correlated with growth [66].
As mentioned earlier AA is the major substrate for the
eicosanoid synthesis and is the precursor of very potent pro-
inflammatory mediators. Multiple studies were able to
demonstrate increased prostaglandins [67,68], thrombox-
anes [20], leukotrienes [69–71] and hydroxyeicosatetraenoic
acids derived from AA in CF. They were increased in blood
[67], breath condensate [65], saliva [69], sputa [70] and
broncho-alveolar lavage fluid [71]. These observations are
directly related to the CF symptoms since these pro-
inflammatory products are responsible for increased mucus
release, neutrophil influx and activation, resulting in addi-
tional inflammation. They cause also broncho- and vaso-
constriction [17–19,23,24].
Inflammation is present very early in the course of the
disease and in absence of bacterial infection [72–74].
Increased inflammation is not only limited to the lungs
but can also be demonstrated in the duodenum [75]. This
leads to the conclusion that CF patients have a predis-
position for inflammation and the defective CFTR contrib-
utes directly to the inflammation.
The excretion of prostanoid metabolites in urine is also
increased [20] and this is not correlated with colonisation,
pulmonary function or genotype. However, a negative
correlation with the phospholipid levels of essential fatty
acids has been demonstrated [20]. This observation supports
the hypothesis concerning the pathological regulation of AA
release in CF since this is the rate limiting step in the
prostanoid production.
This knowledge leads to supplementation trials with
omega-3 fatty acids resulting in a decrease of the AA
derived 5-lipoxygenase products [76].
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transports through membranes. AA inhibits the chloride
channel currents in CF and normal airway epithelium cells
when applied on the cytosolic site of the membrane [77]. It
also reduces the surface expression of sodium channels and
thereby induces a time dependant inhibition of sodium
transport [78].
New knowledge on the role of isoprostanes, formed by
free radicals or reactive oxygen species action on free or
membrane bound PUFAs [79,80] is gathered. CF patients
have increased plasma levels of isoprostanes [81]. They are
not only markers of oxidative stress but have physiological
effects. 8-iso-prostaglandin E2, a peroxidation product of
AA stimulates a transepithelial anion transport mediated by
the CFTR Cl channel [82]. Cowley suggests a direct role
for the isoprostanes in pulmonary host defence which can be
absent in CF due to the CFTR mutation [83].
6.4. Effects of DHA
DHA supplementation inhibits the delta 6-desaturase and
the delta 5-desaturase activity as demonstrated in rat liver
cells [84] and by this way result in a decreased production of
N6 PUFAs. Moreover, long chain N3 FA will compete with
AA for incorporation in phospholipids. Administration of
DHA will result not only in decreased AA concentration in
the phospholipids [84] but also cause a shift in the
eicosanoid production to less potent pro-inflammatory or
anti-inflammatory products, as explained above. However,
there remains controversy in different studies. DHA inhibits
in vitro prostanoid but not leukotriene synthesis [85]. Other
in vivo data were able to demonstrate a decreased
leukotriene production [76].
DHA also selectively augments muscarinic stimulation
of epithelial Cl secretion [86]. The stimulation was more
closely related to the free DHA than to the membrane bound
DHA. Freedman et al. also suggested the existence of a
block in the biosynthesis of DHA leading to a DHA
deficiency in CFTR regulated organs [2], since the
supplementation of a DHA precursor resulted in a DHA
decrease. This resulted in the conclusion that supplementa-
tion should be done with DHA.
Up to now supplementation studies were done with
combined EPA and DHA supplements. An 8 month treat-
ment study demonstrated decreased inflammation measured
by immunoglobulins, a positive effect on pulmonary
function and a decreased antibiotic use [87]. The expected
decrease of AA and increase of LA in membrane
phospholipids was also present [87].7. Conclusion
The disturbance of the fatty acid metabolism can explain
the intrinsic incapacity of the CF patient to control an
environmental challenge and the symptoms as a conse-quence of this. Although according to the results of
Freedman et al. [2] combined EPA and DHA supplementa-
tion could be less valuable, positive effects on inflammation
and pulmonary function are described [87]. Perhaps
supplementation with DHA dominant oils can improve the
results? Question remains to what extend one needs to
supplement [88] and which patients will have the best
benefits of such a supplementation since genotype does
seem to play a role [48]. Although there were no side effects
observed in the supplementation studies up to now and
some clinical improvement has been seen in patients with
CF [51,89], there is still insufficient evidence to recommend
the routine use of omega-3 fatty acids in CF [90]. New
studies using DHA dominant oils with different doses and in
different genotypes have to be performed to answer these
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